Boosting Exosome & Extra-Cellular Vesicle Therapies & Delivery Carriers with Optimal Characterization, Improved Tropism & GMP-Grade Production For Regenerative & Precision Medicine

September 23 - 25, 2025 | Boston, MA

The Industry-Led Forum to Bridge Exosome
Science & Drug Development for Commercialization

The exosome and extracellular vesicles (EV) fields are on the verge of groundbreaking clinical and commercial breakthroughs with therapeutic progress hailed from key biopharma including Rion, Direct Biologics, Aegle Therapeutics, Aruna Bio, EXO Biologics, and more!

Showcasing the biopharma's industry advancements in 2025, the 7th Exosome-Based Therapeutics Development Summit returns to Boston, with never-before-seen data, covering the end-to-end from discovery through to optimized characterization, scalable manufacturing and clinical output, as the only industry-dedicated Summit to bridge the gap between science and business towards effective regenerative and precision medicines.

Join 80+ key exosome and extra-cellular vesicle experts specializing in Exosome Biology, R&D, CMC to Business Development for an unrivalled learning and networking opportunity to roadmap the therapeutic efficacy and delivery potential of exosomes and EVs towards commercialization and patients in need.

OFFICIAL BROCHURE OUT NOW

World-Class Speaker Faculty

News Hub

Brand New Companies for 2025

VesiCURE Therapeutics 7th Exosome-Based Therapeutics Development Summit
Diadem Therapeutics 7th Exosome-Based Therapeutics Development Summit
Xosomix -the 7th Exosome-Based Therapeutics Development Summit
NurExone Biologic - 7th Exosome-Based Therapeutics Development Summit
ABBVIE
EV Therapeutics | 7th Exosome-Based Therapeutics Development Summit
AGS Therapeutics - 7th Exosome-Based Therapeutics Development Summit
Versatope - 7th Exosome-Based Therapeutics Development Summit

Hear From Our Speakers

Sandrine Mores - EXO Biologics

“I look forward to engaging with industry experts to drive innovation, regulatory alignment, and translational success in exosome therapeutics”


Sandra Mores, Chief Operating Officer, EXO Biologics

Chris Paradise - Rion

“As an emerging therapeutic modality, it is essential that leaders in the exosome and EV space come together to exchange knowledge in an effort to accelerate translation of this technology into clinical practice”


Chris Paradise, Vice President – Research & Development, Rion

Events in the Series